All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

What are the future prospects for FLT3 mutated AML?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the AML Hub spoke to Alexander Perl, University of Pennsylvania, Philadelphia, US. We Asked, What are the future prospects for FLT3 mutated acute myeloid leukemia (AML)?

What are the future prospects for FLT3 mutated AML?

Perl begins by outlining the standard of care for patients being treated intensely with newly diagnosed AML and upcoming studies investigating FLT3 inhibitors such as midostaurin, sorafenib, quizartinib, and gilteritinib. He goes on to discuss treatment prospects for patients ineligible for intensive chemo and post transplant maintenance. Finally, he highlights the importance of upcoming study MORPHO, which investigates gilteritinib as posttransplant maintenance.